Liu Yu-Tsueng
Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, 0815, La Jolla, CA 92093, USA.
Infect Disord Drug Targets. 2008 Sep;8(3):183-8. doi: 10.2174/1871526510808030183.
Identification of a causative pathogen is essential for the choice of treatment for most infectious diseases. Many FDA approved molecular assays; usually more sensitive and specific compared to traditional tests, have been developed in the last decade. A new trend of high throughput and multiplexing assays are emerging thanks to technological developments for the human genome sequencing project. The applications of microarray and ultra high throughput sequencing technologies for diagnostic microbiology are reviewed. The race for the $1000 genome technology by 2014 will have a profound impact in diagnosis and treatment of infectious diseases in the near future.
对于大多数传染病而言,确定致病病原体对于治疗方案的选择至关重要。在过去十年中,已经开发出许多获得美国食品药品监督管理局(FDA)批准的分子检测方法;与传统检测相比,这些方法通常更灵敏、更具特异性。由于人类基因组测序项目的技术发展,高通量和多重检测的新趋势正在出现。本文综述了微阵列和超高通量测序技术在诊断微生物学中的应用。到2014年实现1000美元基因组技术的竞争将在不久的将来对传染病的诊断和治疗产生深远影响。